Tarsus Pharmaceuticals Inc

Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease

TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus

Tarsus Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Achievements

Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors

Tarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026